ArticleJournal of gynecologic oncology2026
Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04991051 (HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveRecognition of homologous recombination deficiency (HRD) has revolutionized ovarian cancer (OC) treatment paradigm. Our study aimed to determine the prevalence of HRD in Taiwanese patients with high-grade serous ovarian cancer (HGSOC), high-grade endometrioid ovarian cancer (HGEOC), primary peritoneal cancer (PPC), and/or fallopian tube cancer (FTC).
methodsThe HALO-Taiwan, a cross-sectional, noninterventional study (NCT04991051) enrolled patients with stage III/IV HGSOC, HGEOC, PPC, or FTC having formalin-fixed paraffin-embedded tumor tissue blocks collected within the past 120 days of enrollment. The primary outcome was the prevalence of HRD. The secondary outcomes included prevalence of
resultsOf 68 patients (median age [range]: 60.0 [39.0-81.0] years) enrolled, the majority (92.6%) had primary OC followed by PPC (2.9%) and FTC (4.4%). The overall prevalence of HRD was 52.9%; 14.7% had tumor
conclusionThe HALO-Taiwan was the first observational study reporting HRD prevalence of 52.9% among patients with advanced OC in Taiwan. Our findings underscore the need to implement guideline-recommended testing for HRD as a part of the initial diagnostic work-up for all newly-diagnosed advanced high-grade OC patients to optimize treatment strategies.
trial registrationClinicalTrials.gov Identifier: NCT04991051.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.